[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1121105T1 - Φαρμακοτεχνικη μορφη αταζαναβιρης και κομπισιστατης για θεραπεια hiv - Google Patents

Φαρμακοτεχνικη μορφη αταζαναβιρης και κομπισιστατης για θεραπεια hiv

Info

Publication number
CY1121105T1
CY1121105T1 CY181101050T CY181101050T CY1121105T1 CY 1121105 T1 CY1121105 T1 CY 1121105T1 CY 181101050 T CY181101050 T CY 181101050T CY 181101050 T CY181101050 T CY 181101050T CY 1121105 T1 CY1121105 T1 CY 1121105T1
Authority
CY
Cyprus
Prior art keywords
atazanavir
combisstatis
pharmaceutical form
hiv treatment
treatment
Prior art date
Application number
CY181101050T
Other languages
English (en)
Inventor
Otilia May Yue Koo
Faranak Nikfar
Jing Tao
Niranjan Kumar Kottala
Sailesh A Varia
Original Assignee
Bristol Myers Squibb Holdings Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51743576&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1121105(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Holdings Ireland filed Critical Bristol Myers Squibb Holdings Ireland
Publication of CY1121105T1 publication Critical patent/CY1121105T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Παρουσιάζονται φαρμακοτεχνικές μορφές των HIV ενώσεων αταζαναβίρης και κομπισιστάτης και μέθοδοι θεραπείας χρησιμοποιώντας αυτές τις φαρμακοτεχνικές μορφές.
CY181101050T 2013-10-07 2018-10-18 Φαρμακοτεχνικη μορφη αταζαναβιρης και κομπισιστατης για θεραπεια hiv CY1121105T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361887574P 2013-10-07 2013-10-07
PCT/US2014/059310 WO2015054133A1 (en) 2013-10-07 2014-10-06 Hiv treatment formulation of atazanavir and cobicistat

Publications (1)

Publication Number Publication Date
CY1121105T1 true CY1121105T1 (el) 2019-12-11

Family

ID=51743576

Family Applications (1)

Application Number Title Priority Date Filing Date
CY181101050T CY1121105T1 (el) 2013-10-07 2018-10-18 Φαρμακοτεχνικη μορφη αταζαναβιρης και κομπισιστατης για θεραπεια hiv

Country Status (27)

Country Link
US (2) US20160038502A1 (el)
EP (2) EP3054926B1 (el)
JP (2) JP6574415B2 (el)
KR (1) KR102286386B1 (el)
CN (1) CN106029058A (el)
AU (1) AU2014332200B2 (el)
BR (1) BR112016007526A8 (el)
CA (1) CA2926650A1 (el)
CL (1) CL2016000787A1 (el)
CY (1) CY1121105T1 (el)
DK (2) DK3054926T3 (el)
EA (1) EA031172B1 (el)
ES (2) ES2927484T3 (el)
HR (2) HRP20221126T1 (el)
HU (1) HUE059757T2 (el)
IL (1) IL244881B (el)
LT (2) LT3054926T (el)
MX (1) MX368268B (el)
MY (1) MY178960A (el)
PE (1) PE20160596A1 (el)
PL (2) PL3054926T3 (el)
PT (2) PT3054926T (el)
RS (2) RS57882B1 (el)
SA (1) SA516370891B1 (el)
SG (1) SG11201602501VA (el)
SI (2) SI3421033T1 (el)
WO (1) WO2015054133A1 (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130203759A1 (en) * 2010-04-09 2013-08-08 Faranak Nikfar ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED pH EFFECT
BR112018008651A2 (pt) * 2015-10-30 2018-10-30 Cancer Prevention Pharmaceuticals Inc formulação de combinação de dose fixa de eflornitina e sulindaco
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
US20190175511A1 (en) * 2016-08-08 2019-06-13 Hetero Labs Limited A Multi-Class Anti-Retroviral Composition
US11045423B2 (en) 2016-08-08 2021-06-29 Hetero Labs Limited Anti-retroviral compositions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5558071A (en) * 1994-03-07 1996-09-24 Combustion Electromagnetics, Inc. Ignition system power converter and controller
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
IL134830A0 (en) * 2000-03-01 2001-05-20 Chay 13 Medical Res Group N V Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them
AU2001252201A1 (en) * 2000-03-14 2001-09-24 Amylin Pharmaceuticals, Inc. Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
CN104774275A (zh) * 2006-09-25 2015-07-15 阿彻-丹尼尔斯-米德兰德公司 超吸收性的经表面处理的羧烷基化多糖及其制备方法
CN103435570B (zh) 2007-02-23 2015-06-10 吉里德科学公司 治疗剂的药代动力学特性调节剂
JP2010530889A (ja) * 2007-06-22 2010-09-16 ブリストル−マイヤーズ スクイブ カンパニー アタザナビルを含む錠剤組成物
US20130084243A1 (en) * 2010-01-27 2013-04-04 Liliane Goetsch Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
WO2009084036A2 (en) * 2007-12-20 2009-07-09 Matrix Laboratories Limited Composition for treatment of viral infections
CA2735899A1 (en) * 2008-09-25 2010-04-01 Cephalon, Inc. Liquid formulations of bendamustine
US20110028412A1 (en) * 2009-08-03 2011-02-03 Cappellos, Inc. Herbal enhanced analgesic formulations
US20130203759A1 (en) * 2010-04-09 2013-08-08 Faranak Nikfar ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED pH EFFECT

Also Published As

Publication number Publication date
SA516370891B1 (ar) 2018-08-08
EA031172B1 (ru) 2018-11-30
EP3421033A1 (en) 2019-01-02
US20190358240A1 (en) 2019-11-28
PT3421033T (pt) 2022-09-23
MY178960A (en) 2020-10-26
MX2016004078A (es) 2016-06-06
PT3054926T (pt) 2018-10-26
IL244881A0 (en) 2016-05-31
CN106029058A (zh) 2016-10-12
EA201690594A1 (ru) 2016-09-30
KR20160060764A (ko) 2016-05-30
AU2014332200B2 (en) 2018-10-04
JP2019011334A (ja) 2019-01-24
JP2016532649A (ja) 2016-10-20
IL244881B (en) 2021-12-01
AU2014332200A1 (en) 2016-05-19
PL3054926T3 (pl) 2018-12-31
SI3421033T1 (sl) 2022-11-30
BR112016007526A8 (pt) 2020-03-03
EP3054926A1 (en) 2016-08-17
BR112016007526A2 (pt) 2017-08-01
MX368268B (es) 2019-09-26
DK3421033T3 (da) 2022-10-10
PE20160596A1 (es) 2016-06-15
WO2015054133A1 (en) 2015-04-16
PL3421033T3 (pl) 2022-10-03
JP6574415B2 (ja) 2019-09-11
LT3421033T (lt) 2022-11-10
EP3054926B1 (en) 2018-07-25
CL2016000787A1 (es) 2016-11-25
SG11201602501VA (en) 2016-04-28
CA2926650A1 (en) 2015-04-16
EP3421033B1 (en) 2022-07-27
KR102286386B1 (ko) 2021-08-05
ES2693580T3 (es) 2018-12-12
LT3054926T (lt) 2018-11-12
HRP20181582T1 (hr) 2018-11-30
HRP20221126T1 (hr) 2022-11-25
ES2927484T3 (es) 2022-11-07
SI3054926T1 (sl) 2018-10-30
DK3054926T3 (en) 2018-10-29
HUE059757T2 (hu) 2023-01-28
US20160038502A1 (en) 2016-02-11
RS57882B1 (sr) 2019-01-31
RS63570B1 (sr) 2022-10-31

Similar Documents

Publication Publication Date Title
CY1124729T1 (el) Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου
CY1123633T1 (el) Ετεροκυκλικες ενωσεις και οι χρησεις αυτων
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
CY1121907T1 (el) Συζευγματα antidll3-antiσωmatoς-pbd και χρησεις αυτων
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
CY1124131T1 (el) Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου
CY1125205T1 (el) Φαρμακευτικες συνθεσεις δραστικων απο θεραπευτικη αποψη ενωσεων
CY1120529T1 (el) Προφαρμακα φουμαρικων αλατων και η χρηση τους στην αγωγη ποικιλων νοσων
CY1120862T1 (el) Παραγοντες επαγωγης αποπτωσης για τη θεραπευτικη αγωγη καρκινου και ανοσων και αυτοανοσων ασθενειων
CL2018000813A1 (es) Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso.
DK3142637T3 (da) Keratin treatment formulations and methods
CY1121105T1 (el) Φαρμακοτεχνικη μορφη αταζαναβιρης και κομπισιστατης για θεραπεια hiv
EA201691582A1 (ru) Новые фармацевтические препараты
MA50541A (fr) Formulations pharmaceutiques
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
MA42303A (fr) Formulations pharmaceutiques
MA46867A (fr) Formulations pharmaceutiques
MA54716A (fr) Réduction de la viscosité de formulations pharmaceutiques
MX2015012416A (es) Compuestos heterociclicos y sus usos.
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
MA44987A (fr) Formulations de médicaments améliorées
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
CY1124057T1 (el) Διαμορφωτες υποδοχεων χ ηπατος (lxr)
TR201905218T4 (tr) Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler.
CY1118277T1 (el) Σταθερη φαρμακοτεχνικη μορφη πεξιγανανης